PlasmaChem GmbH is a German SME dedicated to the development, production and sales of medical devices, analytical equipment and nano-materials and their formulations. PlasmaChem was founded in 1993 in Mainz, and in 2005, moved to Berlin- Adlershof, Germany’s leading science and Technology Park. We currently have 10 employees.
The main area of the company concerns nanomaterials, detonation-, vacuum-, plasma- and ultra-thin film technologies and biomedical and technical applications. The main technology of PlasmaChem concerns the development of processes, induced by low temperature plasma on different surfaces, in atomically flat inorganic solids and liquid interfaces. Plasmachem typically performs chemical and low temperature plasma modification of nanopowders and also investigates novel chemical methods for obtaining ultra-dispersed materials. The synthesis methods available in the Company, ranging from wet chemical to plasma-jet syntheses, allow to produce different types of target materials.
The nanomaterials business has two lines: 1) nanomaterials for research purposes, and 2) nanomaterials for industrial use.
In 2005 PlasmaChem launched the world’s first General Catalogue of nano-materials and related products. We manufacture and sell over 100 different nanomaterials through the catalogue to over 2,000 customers worldwide, including leading universities, institutes, and company R&D departments.
PlasmaChem develops applications for its most promising materials and promotes their introduction into industrial markets. Industrial nanopowder products include NanoDiamonds, NanoCeramics, NanoMetals, composite nano- particles, and NanoCapsules. Examples include: additives to electroplating baths (DiamoSilb®, AlumoSilb®, DiamoGold™ and others), additives to lubricating oils (ADDO®) and additives for plastics based on nano-diamond soot and others. These products are supplied to the target industries (oil manufacturers, electro-platers, etc), and private and corporate customers. Both R&D and industrial
products are sold worldwide: 20% in the USA, 60% in the EU and 20% in Asia.
Another branch of the company is active in the development and production of medical devices, such as cardiac stents. In this field, PlasmaChem has introduced two revolutionary technologies on the market: 1) diamond-like coated stents, and
2) multi-layered drug-eluting stents. These two products remain the best performing stents on the market. A new generation of bio-resolvable stents is being developed.